Michele Ciboddo
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
KDM6A loss enhances oxidative phosphorylation uncovering tissue-level convergent evolution.
Journal: The EMBO journal
Published: January 07, 2026
NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.
Journal: Molecular cancer research : MCR
Published: June 03, 2023
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.
Journal: Blood cancer discovery
Published: August 13, 2021
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib.
Journal: Hematological oncology
Published: April 27, 2020
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.
Journal: American journal of hematology
Published: April 04, 2019
JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 04, 2018
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
Journal: Oncotarget
Published: June 07, 2017
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Journal: Oncotarget
Published: January 21, 2017
PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis.
Journal: Leukemia research
Published: August 11, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026